

PE anti-mouse CD115 (CSF-1R) Antibody

Catalog# / Size	135505 / 50 µg 135506 / 200 µg
Clone	AFS98
Regulatory Status	RUO
Other Names	CSF-1R, M-CSFR, c-fms
Isotype	Rat IgG2a, κ
Description	CSF-1R, also known as CD115 and M-CSFR, is a single-pass type I membrane protein and member of the platelet-derived growth factor receptor family. This c-fms (Fms proto-oncogene) gene product's natural ligands include M-CSF and IL-34. Structural studies of CD115 have described an Ig-like extracellular domain, a transmembrane domain, an intracellular juxtamembrane domain, a split tyrosine kinase domain, and a C-terminal tail receptor. Receptor activation induces homodimerization in addition to phosphorylation and ubiquitination of intracellular residues. CD115 directly influences tissue macrophage and osteoclast differentiation and proliferation. It is expressed on monocytes/macrophages, peritoneal exudate cells, plasmacytoid and conventional dendritic cells, and osteoclasts.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration	0.2 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 ⁶ cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes	Additional reported applications (for the relevant formats) include: blocking of ligand binding ¹ . The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays. It has been reported that CD115 can be rapidly internalized, especially when samples are exposed to room temperature. Approximate 33% decrease in CD115 expression has been observed between 0 and 4 hours after sample collection, while overnight incubation of the cells results in complete CD115 downregulation. Pre-treatment with EDTA and low temperatures (2 to 8°C) helps in maintaining surface expression of CD115 ⁴ .
Application References	<ol style="list-style-type: none"> 1. Sudo T, <i>et al.</i> 1995. <i>Oncogene</i> 11:2469. 2. Murayama T, <i>et al.</i> 1999. <i>Circulation</i> 99:1740. 3. Jaeger BN, <i>et al.</i> 2012. <i>J. Exp. Med.</i> 209:565. PubMed 4. Breslin WL, <i>et al.</i> 2013. <i>J Immunol Methods.</i> 390(1-2):1 PubMed 5. Dong L, <i>et al.</i> 2016. <i>Nature.</i> 539:304–308. PubMed
(PubMed link indicates BioLegend citation)	

Product Citations

1. Liang Y, *et al.* 2021. Cell Death Differ. 28:2728. [PubMed](#)
2. Koyama M, *et al.* 2015. J Exp Med. 212: 1303 - 1321. [PubMed](#)
3. Combes F, *et al.* 2018. Neoplasia. 20:848. [PubMed](#)
4. Sierro F, *et al.* 2017. Immunity. 47:374. [PubMed](#)
5. Schloss MJ, *et al.* 2022. Nat Immunol. 23:605. [PubMed](#)
6. Suresh R, *et al.* 2020. J Immunother Cancer. 8: [PubMed](#)
7. Groenen AG, *et al.* 2022. J Lipid Res. 63:100167. [PubMed](#)
8. Tripathi H, *et al.* 2020. J Mol Cell Cardiol. 149:95. [PubMed](#)
9. Bouchareychas L, *et al.* 2021. iScience. 24(8):102847. [PubMed](#)
10. Oliveira-Lima OC, *et al.* 2015. Immunobiology. [PubMed](#)
11. Jackson A, *et al.* 2014. J Leukoc Biol. 92:609. [PubMed](#)
12. Takacs E, *et al.* 2017. J Immunol. 198:239. [PubMed](#)
13. Johnson KD, *et al.* 2022. Blood Adv. 6:1464. [PubMed](#)
14. Tan X, *et al.* 2016. PLoS One. 11: 0160985. [PubMed](#)
15. Lee MH, *et al.* 2018. J Immunol Res. 2018:1601079. [PubMed](#)
16. Bratti M, *et al.* 2022. Front Immunol. 13:1029759. [PubMed](#)
17. Hreha TN, *et al.* 2020. Front Immunol. 11:597916667. [PubMed](#)
18. Sakai M, *et al.* 2020. Immunity. 51(4):655-670. [PubMed](#)
19. Garcia-Agudo LF, *et al.* 2019. FASEB J. :fj201900337R. [PubMed](#)
20. Bowers E, *et al.* 2018. Nat Med. 24:95. [PubMed](#)
21. LeBlond ND, *et al.* 2020. J Lipid Res. 61:1697. [PubMed](#)
22. Yang F, *et al.* 2020. Cancer Res. 80:3677. [PubMed](#)
23. Fuster JJ, *et al.* 2020. Cell Rep. 33:108326. [PubMed](#)
24. Jtte BB, *et al.* 2021. iScience. 24(8):102833. [PubMed](#)
25. Voisin M, *et al.* 2021. Commun Biol. 4:420. [PubMed](#)
26. Eisele AS, *et al.* 2022. Elife. 11: [PubMed](#)
27. Smith C, *et al.* 2012. Cancer Discovery. 2:722. [PubMed](#)
28. Distel E, *et al.* 2014. Circ Res. 115:759. [PubMed](#)
29. He W *et al.* 2018. Immunity. 49(6):1175-1190. [PubMed](#)
30. Barman PK, *et al.* 2019. J Immunol. 202:2720. [PubMed](#)
31. Chen X *et al.* 2017. Cell stem cell. 21(6):747-760. [PubMed](#)
32. Anderson SR, *et al.* 2019. Cell Rep. 27:2002. [PubMed](#)
33. La Rose AM, *et al.* 2021. Mol Metab. 53:101265. [PubMed](#)
34. Kuhn JA, *et al.* 2021. Elife. 10: [PubMed](#)
35. Aktories P, *et al.* 2022. Cell Rep Methods. 2:100260. [PubMed](#)
36. Tripathi H, *et al.* 2020. Stem Cell Rev Rep. 0.953472222. [PubMed](#)
37. Ding P, *et al.* 2022. Bone Res. 10:42. [PubMed](#)
38. Li W, *et al.* 2021. PLoS Pathog. 17:e1009462. [PubMed](#)
39. Gadd V, *et al.* 2016. PLoS One. 11: 0157771. [PubMed](#)
40. Bouchareychas L, *et al.* 2020. Cell Reports. 32(2):107881. [PubMed](#)
41. Wang W, *et al.* 2021. J Am Heart Assoc. 10:e019142. [PubMed](#)
42. Johansson J, *et al.* 2013. J Neurosci. 33:16016. [PubMed](#)
43. Burgener SS, *et al.* 2019. Cell Rep. 27:3646. [PubMed](#)
44. LeBlond ND, *et al.* 2020. J Lipid Res. 61:1697. [PubMed](#)
45. Clemente C, *et al.* 2018. Nat Commun. 9:910. [PubMed](#)
46. Evrard M *et al.* 2018. Immunity. 48(2):364-379. [PubMed](#)
47. Alexander Mildner *et al.* 2017. Immunity. 46(5):849-862. [PubMed](#)
48. Ulrich V, *et al.* 2016. EMBO Mol Med. 8: 643 - 653. [PubMed](#)
49. Mairhofer D, *et al.* 2015. J Invest Dermatol. 135: 2785-93. [PubMed](#)
50. Chen S, *et al.* 2014. Biochem Biophys Res Commun. 446:1002. [PubMed](#)
51. Clemente-Casares X, *et al.* 2017. Immunity. 47:974. [PubMed](#)
52. Foster G, *et al.* 2015. J Immunol. 195: 5380 - 5392. [PubMed](#)
53. Aryal B, *et al.* 2016. Nat Commun. 7:12313. [PubMed](#)
54. Ryu J, *et al.* 2013. Circulation. 127:710. [PubMed](#)
55. Jain A, *et al.* 2020. Nat Immunol. 0.920138889. [PubMed](#)
56. Spiljar M, *et al.* 2021. Cell Metab. 33:2231. [PubMed](#)
57. Hussein M, *et al.* 2015. PLoS One. 10: 0135218. [PubMed](#)
58. Tran S, *et al.* 2020. Immunity. 53(3):627-640.e5. [PubMed](#)
59. Petriello MC, *et al.* 2018. Toxicol Sci. 162:548. [PubMed](#)
60. Steinmetz O, *et al.* 2016. J Infect Dis. 10.1093/infdis/jiv763. [PubMed](#)
61. Yáñez A *et al.* 2017. Immunity. 47(5):890-902. [PubMed](#)
62. Di Liberto G *et al.* 2018. Cell. 175(2):458-471. [PubMed](#)

RRID

AB_1937254 (BioLegend Cat. No. 135505)
AB_1937253 (BioLegend Cat. No. 135506)

Antigen Details

Structure	Ig superfamily, 145 kD
Distribution	Monocytes/macrophages, peritoneal exudate cells, plasmacytoid and conventional dendritic cells, osteoclasts
Function	Growth factor receptor, tyrosine kinase
Ligand/Receptor	Macrophage colony stimulating factor (M-CSF), IL-34

Cell Type	Dendritic cells, Macrophages, Monocytes, Osteoclasts
Biology Area	Immunology
Molecular Family	CD Molecules, Cytokine/Chemokine Receptors
Antigen References	<ol style="list-style-type: none"> 1. Sudo T, <i>et al.</i> 1995 <i>Oncogene</i> 11:2469. 2. Murayama T, <i>et al.</i> 1999 <i>Circulation</i> 99:1740. 3. Goswami S, <i>et al.</i> 2005 <i>Cancer Res.</i> 65:5278. 4. Yu W, <i>et al.</i> 2008 <i>J. Leuko. Biol.</i> 84:852.

Gene ID [12978](#)


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)


Other Formats

Purified anti-mouse CD115 (CSF-1R), PE anti-mouse CD115 (CSF-1R), Biotin anti-mouse CD115 (CSF-1R), APC anti-mouse CD115 (CSF-1R), Alexa Fluor® 488 anti-mouse CD115 (CSF-1R), Brilliant Violet 421™ anti-mouse CD115 (CSF-1R), Brilliant Violet 605™ anti-mouse CD115 (CSF-1R), Brilliant Violet 711™ anti-mouse CD115 (CSF-1R), Alexa Fluor® 594 anti-mouse CD115 (CSF-1R), Purified anti-mouse CD115 (CSF-1R) (Maxpar® Ready), PE/Cyanine7 anti-mouse CD115 (CSF-1R), PerCP/Cyanine5.5 anti-mouse CD115 (CSF-1R), PE/Dazzle™ 594 anti-mouse CD115 (CSF-1R), Alexa Fluor® 647 anti-mouse CD115 (CSF-1R), APC/Cyanine7 anti-mouse CD115 (CSF-1R), TotalSeq™-A0105 anti-mouse CD115 (CSF-1R), APC/Fire™ 750 anti-mouse CD115 (CSF-1R), Ultra-LEAF™ Purified anti-mouse CD115 (CSF-1R), TotalSeq™-B0105 anti-mouse CD115 (CSF-1R), TotalSeq™-C0105 anti-mouse CD115 (CSF-1R)

Product Data



Thioglycolate-elicited BALB/c mouse peritoneal macrophages stained with rat IgG1, k PE and CD11b FITC.



Thioglycolate-elicited BALB/c mouse peritoneal macrophages stained with AFS98 PE and CD11b FITC.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

